A citation-based method for searching scientific literature

Alberto Puccini, Marta Ponzano, Bruna Dalmasso, Irene Vanni, Annalice Gandini, Silvia Puglisi, Roberto Borea, Malvina Cremante, William Bruno, Virginia Andreotti, Eleonora Allavena, Valentino Martelli, Fabio Catalano, Massimiliano Grassi, Maria Laura Iaia, Chiara Pirrone, Alessandro Pastorino, Giuseppe Fornarini, Stefania Sciallero, Paola Ghiorzo, Lorenza Pastorino. Cancers (Basel) 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Michiel S van der Heijden, Jonathan R Brody, David A Dezentje, Eike Gallmeier, Steven C Cunningham, Michael J Swartz, Angelo M DeMarzo, G Johan A Offerhaus, William H Isacoff, Ralph H Hruban,[...]. Clin Cancer Res 2005
134
100

PARP inhibitor combination therapy.
Amy Dréan, Christopher J Lord, Alan Ashworth. Crit Rev Oncol Hematol 2016
125
100

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Suee Lee, Sung Yong Oh, Byung Geun Kim, Hyuk-Chan Kwon, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Jin-Sook Jeong, Hyo-Jin Kim. Am J Clin Oncol 2009
52
100

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
952
100

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
E G Chiorean, D D Von Hoff, M Reni, F P Arena, J R Infante, V G Bathini, T E Wood, P N Mainwaring, R T Muldoon, P R Clingan,[...]. Ann Oncol 2016
67
100

Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer.
Stefan Heinrich, Daniela Kraft, Elsbeth Staib-Sebler, Wolfram Schwarz, Christiane Gog, Thomas Vogl, Matthias Lorenz. Hepatogastroenterology 2013
4
100

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Rachna T Shroff, Andrew Hendifar, Robert R McWilliams, Ravit Geva, Ron Epelbaum, Lindsey Rolfe, Sandra Goble, Kevin K Lin, Andrew V Biankin, Heidi Giordano,[...]. JCO Precis Oncol 2018
114
100

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
100

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, Emily Lyons, Patricia DeArbeloa, Andrew Hendifar, Sam Mikhail, Vincent Chung, Vaibhav Sahai, Davendra P S Sohal,[...]. Lancet Oncol 2020
192
100

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
Li-Tzong Chen, Teresa Macarulla, Jean-Frédéric Blanc, Beloo Mirakhur, Floris A de Jong, Bruce Belanger, Tanios Bekaii-Saab, Jens T Siveke. Cancers (Basel) 2019
12
100

Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C.
Xiaomin Chen, Fangfei Peng, Yan Ji, Honggang Xiang, Xiang Wang, Tingting Liu, Heng Wang, Yumin Han, Changxu Wang, Yongfeng Zhang,[...]. Cell Death Dis 2020
2
100

Cancer statistics, 2022.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2022
100

Genetic susceptibility to pancreatic cancer.
Alison P Klein. Mol Carcinog 2012
151
100

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
Eileen M O'Reilly, Jonathan W Lee, Mark Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A Lowery, Joanne F Chou, Vaibhav Sahai,[...]. J Clin Oncol 2020
160
100

Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
Pedro L S Uson, N Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, Mitesh J Borad, Daniel Ahn, Mohamad B Sonbol, Douglas O Faigel, Norio Fukami, Rahul Pannala,[...]. Clin Transl Gastroenterol 2021
7
100



Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
Samir El-Ghobashy, Tarek R El-Leithy, Mamdouh M Roshdy, Hossam M El-Ganzoury. J Egypt Natl Canc Inst 2007
8
100

Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
Labrinus van Manen, Jesse V Groen, Hein Putter, Alexander L Vahrmeijer, Rutger-Jan Swijnenburg, Bert A Bonsing, J Sven D Mieog. Biomarkers 2020
21
100

Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Vladimir M Moiseyenko, Vyacheslav A Chubenko, Fedor V Moiseyenko, Albina S Zhabina, Tatiana V Gorodnova, Yuri I Komarov, Alexey A Bogdanov, Anna P Sokolenko, Evgeny N Imyanitov. Med Oncol 2014
17
100

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Mark Yarchoan, Melinda C Myzak, Burles A Johnson, Ana De Jesus-Acosta, Dung T Le, Elizabeth M Jaffee, Nilofer S Azad, Ross C Donehower, Lei Zheng, Paul E Oberstein,[...]. Oncotarget 2017
51
100

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ning Ren, Leyin Zhang, Jieru Yu, Siqi Guan, Xinyang Dai, Leitao Sun, Minli Ying. Front Oncol 2021
1
100

Early Detection of Pancreatic Cancer: Opportunities and Challenges.
Aatur D Singhi, Eugene J Koay, Suresh T Chari, Anirban Maitra. Gastroenterology 2019
235
100

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Maria C Villarroel, N V Rajeshkumar, Ignacio Garrido-Laguna, Ana De Jesus-Acosta, Siân Jones, Anirban Maitra, Ralph H Hruban, James R Eshleman, Alison Klein, Daniel Laheru,[...]. Mol Cancer Ther 2011
184
100

Involvement of Brca2 in DNA repair.
K J Patel, V P Yu, H Lee, A Corcoran, F C Thistlethwaite, M J Evans, W H Colledge, L S Friedman, B A Ponder, A R Venkitaraman. Mol Cell 1998
502
100


Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
Siân Jones, Ralph H Hruban, Mihoko Kamiyama, Michael Borges, Xiaosong Zhang, D Williams Parsons, Jimmy Cheng-Ho Lin, Emily Palmisano, Kieran Brune, Elizabeth M Jaffee,[...]. Science 2009
558
100


Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Maeve A Lowery, Winston Wong, Emmet J Jordan, Jonathan W Lee, Yelena Kemel, Joseph Vijai, Diana Mandelker, Ahmet Zehir, Marinela Capanu, Erin Salo-Mullen,[...]. J Natl Cancer Inst 2018
124
100

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy.
Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G Papavassiliou, Michalis V Karamouzis. World J Gastrointest Oncol 2020
70
100


NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Andrea Wang-Gillam, Richard A Hubner, Jens T Siveke, Daniel D Von Hoff, Bruce Belanger, Floris A de Jong, Beloo Mirakhur, Li-Tzong Chen. Eur J Cancer 2019
96
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.